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Rotterdam, the Netherlands; Shefﬁeld and London, United Kingdom; and Bern, SwitzerlandObjectives This study aimed to update the Logistic Clinical SYNTAX score to predict 3-year survival after
percutaneous coronary intervention (PCI) and compare the performance with the SYNTAX score alone.
Background The SYNTAX score is a well-established angiographic tool to predict long-term outcomes
after PCI. The Logistic Clinical SYNTAX score, developed by combining clinical variables with the
anatomic SYNTAX score, has been shown to perform better than the SYNTAX score alone in predicting
1-year outcomes after PCI. However, the ability of this score to predict long-term survival is unknown.
Methods Patient-level data (N¼ 6,304, 399 deaths within 3 years) from 7 contemporary PCI trials were
analyzed. We revised the overall risk and the predictor effects in the core model (SYNTAX score, age,
creatinine clearance, and left ventricular ejection fraction) using Cox regression analysis to predict
mortality at 3 years. We also updated the extended model by combining the core model with
additional independent predictors of 3-year mortality (i.e., diabetes mellitus, peripheral vascular
disease, and body mass index).
Results The revised Logistic Clinical SYNTAX models showed better discriminative ability than the
anatomic SYNTAX score for the prediction of 3-year mortality after PCI (c-index: SYNTAX score, 0.61;
core model, 0.71; and extended model, 0.73 in a cross-validation procedure). The extended model in
particular performed better in differentiating low- and intermediate-risk groups.
Conclusions Risk scores combining clinical characteristics with the anatomic SYNTAX score
substantially better predict 3-year mortality than the SYNTAX score alone and should be used for long-
term risk stratiﬁcation of patients undergoing PCI. (J Am Coll Cardiol Intv 2014;7:464–70) ª 2014 by
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and Acronyms
ACEF = age, creatinine
clearance, ejection fraction
BMI = body mass index
CABG = coronary artery
bypass graft
NERS = New Risk
Stratiﬁcation
PCI = percutaneous coronary
intervention
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465The SYNTAX score, ﬁrst used in the landmark SYNTAX
(SYNergy between percutaneous coronary intervention with
TAXus and cardiac surgery) trial (1), is a well-established
angiography-based anatomic tool to risk-stratify patients
with coronary artery disease undergoing percutaneous cor-
onary intervention (PCI) (2). The SYNTAX score has been
validated in a number of contemporary studies conﬁrming its
utility in predicting PCI outcomes (3–5).
The addition of clinical variables to the SYNTAX score
has been shown to improve the ability of this score to
predict adverse outcomes (6,7). The Logistic Clinical
SYNTAX score was developed and cross-validated using
1-year follow-up data from >6,000 patients in 7 contem-
porary coronary stent trials (7). The score was externally
validated in the ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) trial (8). However,
this score has not been evaluated to predict longer-term
survival after PCI. Three-year outcomes in all 7 coronary
stent trials used to develop and validate this score have
become available. This study, therefore, aimed to update
Logistic Clinical SYNTAX score for predicting 3-year
survival after PCI.
Methods
Data collection and analysis. Patient-level data (N ¼
6,304) from 7 coronary stent trials (SIRTAX [Sirolimus-
Eluting Versus Paclitaxel-Eluting Stents for Coronary
Revascularization] [9], ARTS II [Arterial Revascularization
Therapies Study II] [10], STRATEGY [Single High Dose
Bolus Tiroﬁban and Sirolimus Eluting Stent vs Abciximab and
Bare Metal Stent in Myocardial Infarction] [11], MULTI-
STRATEGY [Multicentre Randomised Study Comparing
Tiroﬁban Administered With the Single High-Dose Bolus
Versus Abciximab and Sirolimus Eluting Stent Versus Bare
Metal Stent in Acute Myocardial Infarction] [12], LEADERS
[Limus Eluted From A Durable Versus ERodable Stent
Coating] [13], SYNTAX [1], and RESOLUTE All-
Comers [Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent] [14])
were pooled for the present study, as described previously
(6,7). The endpoint of this prognostic analysis was 3-year
all-cause death.
Data are presented as mean  SD and percentage or
proportion, as appropriate. Univariate and multivariable Cox
regression analyses were performed to assess associations
between patient characteristics and 3-year mortality. All
analyses were adjusted for the coronary stent trial. To allow
for a direct comparison of the prognostic value of predictors
recorded in different units or scales, the hazard ratios for
the continuous predictors were estimated for a change from
the 25th to 75th percentile of the predictor distribution.
Statistical analyses were performed with R software version
2.13.1 (R Foundation for Statistical Computing, Vienna,Austria) and SPSS version 21.0 (SPSS, Inc., Chicago,
Illinois).
Model development and validation. We incorporated the
anatomic SYNTAX score (2) and components of the age,
creatinine clearance, ejection fraction (ACEF) score (15) in
a Cox regression model (Logistic Clinical SYNTAX,
core model), as previously described (7). We developed an
extended model by combining the core model predictors
with additional clinical variables independently predicting
3-year mortality in Cox regression model. The discrimina-
tive ability of the models was assessed with c-index. The
agreement between observed and predicted risks was
assessed with calibration plots (16). Cross-validation was
performed, as previously described (7).
The ﬁnal model is presented as a score chart. Scores were
calculated by dividing the products of regression coefﬁcients
and predictor values by the smallest product. A constant was
subtracted or added to rescale the scores in positive integers.
The sum scores were then related to 2- and 3-year risk of
mortality.Results
Patient characteristics and univar-
iate predictors of mortality. The
7 trials comprised 6,304 patients
with a mean age of 64  11
years, SYNTAX score 17  11,
creatinine clearance 91  36
ml/min, ejection fraction 56 
12%, and body mass index
(BMI) of 28  4 kg/m2.
There were 399 deaths over the 3-year follow-up (cu-
mulative risk, 6.3%), of which 175 were within the ﬁrst year.
The univariate predictors of mortality included the
SYNTAX score, ACEF, female sex, BMI, peripheral
vascular disease, diabetes mellitus, hyperlipidemia, previous
myocardial infarction, and previous stroke (Table 1).
Model development. The original Logistic Clinical
SYNTAX score underpredicted the risk of 3-year mortality
(Online Fig. 1). Hence, the revision of the model included
both revising the strength of the predictor effects and the
overall risk.
The Cox regression analysis showed that each component
of the Logistic Clinical SYNTAX core model (i.e., the
SYNTAX score and ACEF) still predicted 3-year all-cause
mortality (Table 2). Several variables (e.g., presentation,
previous myocardial infarction, and smoking) of the original
extended model showed a relatively weak effect and were not
used in a revised extended model to develop a parsimonious
score chart (Online Fig. 2). Because the overall risk for
patients from the SYNTAX trial was higher (10.6% cu-
mulative 3-year risk) compared with the mean of the other
Table 1. Univariate Association of Patient Characteristics With
Death After PCI
Follow-Up Period, yrs
0–3 0–1 1–3
Total no. of patients 6,304 6,304 6,084
No. lost to follow-up 114 45 69
Deaths* 399 (6.3) 175 (2.8) 224 (3.7)
SYNTAX score (23 vs. 8)y 1.6 (1.4–1.8) 1.8 (1.5–2.2) 1.4 (1.2–1.7)
Age (72 yrs vs. 56 yrs)y 2.9 (2.5–3.4) 2.8 (2.2–3.6) 3.0 (2.4–3.8)
Creatinine clearance (109 ml/min
vs. 67 ml/min)y
2.1 (1.9–2.4) 2.2 (1.9–2.6) 2.0 (1.7–2.3)
LV ejection fraction (40% vs. 50%)y 1.9 (1.7–2.2) 2.5 (1.4–4.7) 1.7 (1.4–2.1)
Presentation
Non–ST-segment elevation MI 1.3 (1.0–1.8) 1.7 (1.1–2.8) 1.1 (0.7–1.7)
ST-segment elevation MI 1.2 (0.9–1.7) 1.8 (1.1–2.9) 1.0 (0.6–1.5)
Female sex 1.3 (1.1–1.7) 1.5 (1.1–2.1) 1.2 (0.9–1.6)
Body mass index (30 kg/m2
vs. 25 kg/m2)y
1.1 (1.1–1.2) 1.1 (1.0–1.2) 1.2 (1.1–1.3)
Peripheral vascular disease 2.5 (1.8–3.6) 2.4 (1.6–3.7) 2.6 (1.6–4.3)
Diabetes
Noninsulin dependent 1.7 (1.3–2.1) 2.1 (1.4–2.9) 1.4 (1.0–2.0)
Insulin dependent 2.5 (1.9–3.4) 3.1 (2.0–4.8) 2.1 (1.4–3.2)
Hypertension 1.3 (1.0–1.6) 1.6 (1.1–2.3) 1.1 (0.8–1.5)
Hyperlipidemia 0.7 (0.6–0.8) 0.6 (0.5–0.9) 0.8 (0.6–1.0)
Smoking
Previous 0.8 (0.6–1.1) 0.7 (0.5–1.1) 0.9 (0.6–1.3)
Current 0.8 (0.6–1.1) 0.7 (0.4–1.1) 0.8 (0.5–1.3)
Previous MI 1.4 (1.1–1.8) 1.7 (1.2–2.4) 1.1 (0.8–1.6)
Previous PCI 0.9 (0.7–1.2) 0.6 (0.4–1.0) 1.1 (0.8–1.6)
Previous TIA or stroke 1.7 (1.2–2.4) 1.3 (0.6–2.8) 1.6 (0.8–3.5)
Second-generation DES 0.8 (0.5–1.2) 0.9 (0.5–1.6) 0.7 (0.4–1.3)
Values are n, n (%), or hazard ratio (95% conﬁdence interval). *Cumulative risk of overall
mortality according to Kaplan-Meier analyses. yHazard ratio is given for the change from the
25th percentile to the 75th percentile of the predictor distribution.
DES ¼ drug-eluting stents; LV ¼ left ventricular; MI ¼ myocardial infarction; PCI ¼ percu-
taneous coronary intervention; TIA ¼ transient ischemic attack.
Table 2. Multivariable Associations of the Components of the
Logistic Clinical SYNTAX Model With 3-Year All-Cause Death
Core Model Extended Model
SYNTAX score (23 vs. 8)* 1.31 (1.13–1.52) 1.30 (1.12–1.51)
Age (72 yrs vs. 56 yrs)* 1.98 (1.62–2.41) 2.05 (1.68–2.51)
Creatinine clearance (109 ml/min
vs. 67 ml/min)*
1.50 (1.30–1.73) 1.48 (1.26–1.73)
LV ejection fraction (40% vs. 50%)* 1.72 (1.50–1.97) 1.63 (1.50–1.97)
Presentation
Non–ST-segment elevation MI 1.23 (0.90–1.70)
ST-segment elevation MI 1.22 (0.86–1.73)
Body mass index (30 kg/m2 vs. 25 kg/m2)* 1.14 (1.06–1.22)
Peripheral vascular disease 1.81 (1.26–2.59)
Previous MI 1.23 (0.98–1.54)
Smoking 1.16 (0.82–1.63)
Diabetes
Noninsulin dependent 1.37 (1.05–1.75)
Insulin dependent 1.55 (1.12–2.16)
Values are hazard ratio (95% conﬁdence interval). *Hazard ratio is given for the change from the
25th percentile to the 75th percentile of the predictor distribution.
Abbreviations as in Table 1.
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466trials (5.6%), a score of 2 was assigned for SYNTAX-like
patients (Fig. 1).
Model performance and validation. The c-index was sub-
stantially higher for the core and extended models of
revised Logistic Clinical SYNTAX score compared with
the SYNTAX score alone (SYNTAX score, 0.61; core model,
0.71; extended model, 0.73; likelihood ratio test, p < 0.01).
This pattern was consistent in the individual trials
(Online Table 1). The extended model in particular per-
formed better in differentiating low- and intermediate-risk
groups (Fig. 2). Cross-validation conﬁrmed a reasonably good
agreement between the observed and predicted risks, although
SIRTAX patients had some underestimation of risk, with
5.1% mortality compared with 3.0% predicted risk (Fig. 3).
Discussion
The data presented here highlight that incorporating clinical
variables into the risk model together with the anatomicSYNTAX score considerably improved the ability of the
SYNTAX score to predict longer-term mortality. The
clinical variables independently predicting 3-year mortality
in our database included older age, renal dysfunction, left
ventricular systolic dysfunction, diabetes mellitus, extremes
of body weight, and peripheral vascular disease.
Predictors of mortality after PCI. The SYNTAX score is an
angiography-based tool constructed during the design of the
SYNTAX trial to describe numerically the extent and
complexity of coronary artery disease. This score has been
shown to predict PCI outcomes (17–19) and has been
incorporated into the European and American revasculari-
zation guidelines to help in the appropriate selection of
a revascularization strategy (17,20). Clinical predictors of
3-year all-cause mortality after PCI included the variables in
the ACEF score along with diabetes mellitus, BMI, and
peripheral vascular disease. The ACEF score has been
shown to be comparable to the EuroSCORE in predicting
outcomes (15). Diabetes mellitus is an important predictor
of poor outcomes after PCI. Diabetes was not included in
the recently developed SYNTAX score II as it did not show
any interaction with treatment (PCI or coronary artery
bypass graft [CABG]) in the SYNTAX trial (21) and was
therefore not considered important in decision making be-
tween CABG and PCI, which is the main objective of
the SYNTAX score II. In the current study, diabetes was an
important determinant of outcomes after PCI, in line with
other reports (7,22). The impact of obesity on PCI outcomes
has also remained debatable. Some studies have shown an
“obesity-paradox” (i.e., obese patients having better out-
comes after PCI). However, once adjusted for other clinical
Figure 1. Updated Logistic Clinical SYNTAX Score
Variables with scoring points in the updated Logistic Clinical SYNTAX score for
the prediction of 3-year mortality (A) and correlation of the sum score with
predicted absolute risk of mortality (B). *SYNTAX-like patient was deﬁned as
fulﬁlling the enrollment criteria for the SYNTAX trial (i.e., left main stem or
3-vessel disease). BMI ¼ body mass index; CrCl ¼ creatinine clearance; LV-
EF ¼ left ventricular ejection fraction; PVD ¼ peripheral vascular disease.
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467variables, this may not hold true. Our results are consistent
with those of other studies showing poor prognosis in obese
(23) as well as underweight patients (24,25). Peripheral
vascular disease is another important factor in determining
outcomes after PCI, as shown in our analysis and previous
studies (26–28).
Comparison with other tools. A number of PCI risk scores
are available, which highlights the importance of risk strat-
iﬁcation but also causing confusion as to which model to use.
All of these tools have their strengths and weakness, and no
score is perfect. The National Cardiovascular Data Registry
score (29), the Mayo Clinical Risk score (30), the EuroHeart
PCI score (31), and the New York PCI risk score (32) have
been validated to predict in-hospital or short-term outcomesafter PCI. Although patients and clinicians may wish to
know the short-term risk of complications associated with
PCI, a longer-term perspective is equally vital. The New
Risk Stratiﬁcation (NERS) score provides such longer-term
prognostic estimates. However, the NERS score, a complex
score consisting of 17 clinical, 33 anatomic, and 4 procedural
variables, categorizes patients into levels of risk (high and
low risk) without giving an individualized risk assessment
(33). The NERS-II score (7 clinical and 9 angiographic
variables) has been shown to predict major adverse cardiac
events at 1 year in patients undergoing PCI for unprotected
left main stem disease (34).
The SYNTAX score has been validated in multiple
studies to predict both short- and long-term outcomes
(17–19). This score is also not a simple score to calculate but
is facilitated by the availability of an online calculator (35)
and has been shown to have good reproducibility after
appropriate training (36). Inclusion of the patient’s clinical
risk proﬁle can augment the predictive performance of the
anatomic SYNTAX score (6,7). The Global Risk score,
developed by combining the SYNTAX score with the
EuroSCORE, has been shown to improve predictive power
of the SYNTAX score (37–39); however, this score is rather
complex as the EuroSCORE is composed of 17 variables.
The Clinical SYNTAX score was, therefore, developed by
multiplying the SYNTAX score with the ACEF score and
has been shown to improve mortality predictions compared
with the SYNTAX score alone (6). However, this score was
overestimating the risk of adverse events (poor calibration)
and did not discriminate low- and intermediate-risk groups
well. The Logistic Clinical SYNTAX score was developed
to individualize risk and provide 1-year predictions in an all-
comers PCI population. The current model, presented in
this paper, extends this score to provide longer-term prog-
nostic information after PCI.
Clinical application. The SYNTAX trial is the largest
contemporary trial comparing PCI and CABG for the
treatment of complex coronary artery disease. A number of
prognostic models, with distinct utility and objectives, has
been derived from this trial, as highlighted in Table 3.
Brieﬂy, the anatomic SYNTAX score should be used for
angiographic characterization of extent and severity of cor-
onary artery disease, the SYNTAX score II should be used
for decision making for PCI versus CABG, and the updated
Logistic Clinical SYNTAX score (presented in this paper)
should be used to predict long-term outcomes after PCI.
Study limitations. Although the Clinical SYNTAX score is
derived from contemporary stent trials and cross-validated,
further evaluation in real-world, all-comer registries and
external validation is warranted. Head-to-head comparisons
of various scores, for example, Logistic Clinical SYNTAX
and the Global Risk score, are useful, but have not been
performed because the EuroSCORE is not collected in all
stent trials used in this study. Cardiogenic shock, which is a
Figure 3. Calibration Plots at Cross-Validation of Updated Logistic Clinical SYNTAX Score
Calibration plots at cross-validation for the 4 coronary stent trials with all predictors recorded for the extended model. Plots are shown for the extended model
predicting 3-year all-cause mortality. The triangles indicate the observed frequencies by quintile of predicted probabilities. Good agreement was evident between
observed and predicted risks. ARTS II ¼ Arterial Revascularization Therapies Study II; K-M ¼ Kaplan-Meier; LEADERS ¼ Limus Eluted From A Durable Versus ERodable
Stent Coating; SIRTAX ¼ Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization; SYNTAX ¼ TAXUS Drug-Eluting Stent Versus Coronary Artery
Bypass Surgery for the Treatment of Narrowed Arteries.
Figure 2. Survival Based on SYNTAX Score, Core Model, and Extended Model
Kaplan-Meier survival curves for low, intermediate, and high tertiles based on the SYNTAX score, core model, and extended model.
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Table 3. Application and Utility of Various SYNTAX-Based Scores
Score Components Objective Current Status
SYNTAX score Anatomic (angiographic) Assessment of the location, extent and complexity
of coronary artery disease
Widely accepted; incorporated in international
guidelines; imposed by FDA in future trials
Functional SYNTAX score Anatomic þ functional ﬂow
reserve
As SYNTAX score but based on hemodynamically
signiﬁcant lesions
Limited use as further invasive (pressure wire)
assessment of the coronary arteries is required
Residual SYNTAX score Recalculation of the SYNTAX
score after PCI
A marker of completeness of revascularization by PCI Awaiting validation studies
CABG SYNTAX score Residual SYNTAX score after CABG A marker of completeness of revascularization by CABG Awaiting validation studies
Global Risk score SYNTAX score þ EuroSCORE To improve predictive power of the SYNTAX score Limited use due to complex nature of this score
Clinical SYNTAX score SYNTAX score,* ACEF score To improve predictive power of the SYNTAX score Superseded by Logistic Clinical SYNTAX score
Logistic Clinical
SYNTAX score
SYNTAX score þ ACEF score To improve predictive power of the SYNTAX score Original model to predict 1-yr outcomes;
updated model to predict 3-yr mortality;
external validation needed
SYNTAX score II SYNTAX score þ clinical variables Decision making for PCI vs. CABG Awaiting prospective validation
ACEF ¼ age, creatinine clearance, ejection fraction; CABG ¼ coronary artery bypass grafting; FDA ¼ U.S. Food and Drug Administration; PCI ¼ percutaneous coronary intervention.
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469risk factor for adverse outcomes (32,40), was under-repre-
sented in these stent trials; caution is warranted in the
application of our score in this patient group. Finally, no
risk-scoring system is perfect, and a careful heart team
evaluation remains vital in decision making (41).Conclusions
Compared with the SYNTAX score alone, the updated
Logistic Clinical SYNTAX score substantially enhances
the risk stratiﬁcation for mortality at 3 years and allows for
an individualized risk assessment of patients undergoing
PCI. Our ﬁndings reinforce the need for a combined
anatomic-clinical approach to ascertain long-term prog-
nosis after PCI.Acknowledgments
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